U.S. pharma huge copyright scrapped two experimental weight loss capsules previous yr—a the moment-daily capsule, lotiglipron, because of elevated liver enzymes in addition to a twice-every day tablet, danuglipron, as a result of robust Unwanted effects—but CEO Albert Bourla has claimed the company is determined to “play and acquire” in the